This presentation probably gives a good overview of the Clinical Data Management work at a high level.
https://globalhealthtrials.tghn.org/site_media/media/articles/QAWhat_is_clinical_data_management.pdf
This presentation probably gives a good overview of the Clinical Data Management work at a high level.
https://globalhealthtrials.tghn.org/site_media/media/articles/QAWhat_is_clinical_data_management.pdf
that’s because trigyn is listed on both NSE and BSE and this rule applies to “BSE only” listed companies. Clearly this is a very stupid thing to do and i hope this move encourages companies to list on NSE as well … also just like you have started calculating the maximum possible gains that can come in a stock, a lot of others would start doing it and this will only encourage trading. In my opinion we should all call at the numbers listed on that BSE notice and sound our displeasure to them.
Congnizant healthcare practice seems to be big, contributing almost 1/3rd of their revenue.
Trying to study more about their abilities in clinical data management and drug safety field which would be a more like to like comparison with take sol.
Healthnet was acquired by Centene and not congnizant http://marketrealist.com/2015/07/centene-announces-acquisition-health-net/
On Trizettto
Congnizant’s press release says http://news.cognizant.com/2014-11-20-Cognizant-Completes-Acquisition-of-TriZetto-Creating-a-Fully-Integrated-Healthcare-Technology-and-Operations-Leader
“TriZetto software manages the health benefits of close to half the insured population of the U.S. and supports about a quarter of all U.S. care providers. The company is now a part of Cognizant’s healthcare practice whose clients include 16 of the top 20 U.S. health plans, and four of the top five pharmacy benefit management companies.”
So this seems a different kind of work than what Take does.
$ 80-90/tonne might be a good range.
But entirely depend on the context.
Is there any rule for max gain of bse listed stocks on weekly, monthly and yearly basis?
I read somewhere about only BSE listed stocks that BSE has put cap on stocks that can gain on weekly, monthly and yearly basis. I am not sure about that. How that works.
Here is the reference: http://value-picks.blogspot.in/2015/08/bse-to-introduce-stringent-circuit.html?m=0
It’s there any rule for a max gain in weekly, monthly and yearly basis on BSE listed stocks? I read that news somewhere but not sure about that. Does that condition apply to Keerthi?
Hey Ashish, I think you’re being too kind. In my view, based on my personal and anecdotal experience, way more than 25% of initial inventory is sold to brokers / other speculators. These speculators for example buy a 5,000 Rs/sqft villa by paying just 1000/sqft (mortgage, 20% of prop value) wait for a few months and sell the villa in a few months for 5300 /sq ft (5% appreciation in villa prices), but a 30% return on their invested capital.
That being said though, I think it is almost irrelevant from Arvind infra’s perspective. Irrespective of who the buyer is (end user or speculator) Arvind get’s the money which reduces working cap and enables them to construct.
Additionally, land Speculator and real estate brokers have a really good grip of their respective markets. If they are snapping up these villas, they expect a pretty good appreciation /demand for it (otherwise why would they buy it)
Am i missing something out? I think bookings are a good barometer of assessing the perceived attractiveness of a real estate project.
On a totally side note, since we are on the subject – An interesting panel discussion on the current real estate scene (Motilal oswal real estate panel) Link below.
@Sarav can you please check how Krebs has done in last 15 years. I remember buying this stock around 2000 and gave up on it as it didn’t do much
Yup, heard the last 2 concalls. Mgmt. seemed very optimistic.
However, to understand if the optimism is well placed, we should study more on industry from various sources/perspectives to get a well rounded view.
If you come across anything please share.
On the EBITDA front, yes we should see subdued margins for next few quarters or probably a year or 2.
It takes time to integrate a acquisition.
As highlighted by Admin and moderators please refrain from saying things such as “It may become a 5 Bagger in next 5 years from these levels.”
That may cause naive investors to invest without understanding much on business/industry and that’s not what we are trying to achieve at VP.
Concentrate more on providing facts and information about company/industry/competitors etc.
If you have worked on revenue/EBITDA/PAT estimates for next few years, that would be great to share i think.
Ajanta no longer looks so expensive on a comparative basis after the recent correction. I have just started adding some more after 7 months waiting for it to correct. I recommend buying some at this level.
Disclosure: Ajanta forms 30% of my portfolio, accumulating since 2 years
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!